• About Us
    • About EirGenix
    • Milestones
    • Vision and Mission
    • Facilities and Capacities
      • Xizhi Facility
      • Zhubei Facility
    • Management Team
    • Videos
    • 360-Degree Virtual Tour
  • News
    • News
    • Events
  • Services
    • Cell Line Development
    • Process Development
    • Analytical & Quality Control
    • cGMP manufacturing–mammalian system
    • cGMP manufacturing–microbial system
    • Antibody-Drug Conjugate
  • Products
    • PRODUCT PIPELINE
    • CRM197 CARRIER PROTEIN
    • COVID-19 ANTIGEN RAPID TEST
  • Investor
    • Financials
      • Monthly Revenue
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
      • Financial Reports
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
    • Corporate Governance
      • Corporate Governance
      • Board of Directors
      • Internal Audit
    • Shareholder Services
      • Shareholders' Meeting
      • Investor Conference
      • Dividend Distribution
      • Market Observation Post System
      • Investor Relations & Media Contact
      • Stock Transfer Agent
    • ESG
      • ESG Overview
  • Recruiting
  • Contact Us
| English | 繁體中文
EN
  • EN
  • 繁中
  • LINKEDIN
  • YOUTUBE
  • Home
  • News
  • Events
News
  • News
    • EirGenix rated top 5% Corporate Governance Evaluation at TPEx after second year of the IPO
    • EIRGENIX ACHIEVES THE FIFTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
    • MARKETING AUTHORIZATION APPLICATION (MAA) SUBMITTED FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR TO EMA
    • BIOLOGICS LICENSE APPLICATION (BLA) SUBMITTED TO U.S FDA FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR
    • EG12014'S PHASE III CLINICAL TRIAL INTERIM RESULTS PUBLISHED AT SAN ANTONIO BREAST CANCER SYMPOSIUM
    • EirGenix Completed Its NTD 5.03 Billion Private Placement on the Fifteenth of October
    • EIRGENIX ACHIEVES THE FOURTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
    • HONG HAI/FOXCONN FOUNDER TERRY GUO ANNOUNCES INVESTMENT TO ACCELERATE EIRGENIX’S GLOBAL EXPANSION
    • POSITIVE PHASE III CLINICAL RESULTS FOR EIRGENIX'S PROPOSED TRASTUZUMAB BIOSIMILAR
    • EIRGENIXは日本市場を拡大するために、日本の会社と長期供給契約の締結について
    • EIRGENIX COMPLETES NEOADJUVANT TREATMENT AND SURGERY FOR LAST PATIENT IN PHASE III CLINICAL TRIAL
    • VSTRIP® COVID-19 ANTIGEN RAPID TEST VALIDATED AND APPROVED IN INDIA!
    • EIRGENIX ACHIEVES THE THIRD MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
    • EIRGENIX RECEIVES 2020 BIOPROCESSING EXCELLENCE IN GREATER CHINA REGION AWARD!
    • EIRGENIX ACHIEVES THE SECOND MILESTONE OF ITS BIOSIMILAR TRASTUZUMAB - LICENSING AGREEMENT
    • EIRGENIX RECEIVES APPROVAL FROM JAPAN'S PMDA
    • EIRGENIX'S REVENUE REACHES A RECORD HIGH IN JUNE
    • EIRGENIX COLLECTS ITS INITIAL SIGNING FEE DAYS BEFORE ITS OFFICIAL IPO
    • EIRGENIX INC. ANNOUNCES 3-DAY STOCK OPTION BIDDING AHEAD OF ITS LATE-JUNE IPO
    • EIRGENIX HOLDS ITS PRE-IPO PRESS CONFERENCE
    • EIRGENIX SIGNS TRASTUZUMAB BIOSIMILAR LICENSE AGREEMENT WITH NOVARTIS SANDOZ
    • EIRGENIX AWARDED FOR ITS INNOVATION AT THE NATIONAL INDUSTRIAL INNOVATION AWARDS
    • EIRGENIX, INC. WINS BEST BIOPROCESS EXCELLENCE IN TAIWAN AWARD
    • EIRGENIX, INC. OFFICIALLY OPENS ITS NEW WORLD-CLASS COMMERCIAL MASS PRODUCTION FACILITY
    • EIRGENIX'S PHASE III CLINICAL TRIAL OF EG12014 HAS ENROLLED FIRST PATIENT
    • CANCER THERAPEUTIC DRUG EG12014 IS APPROVED FOR PHASE III CLINICAL TRIAL
    • EIRGENIX IS AWARD TOP 145 OF THE TECHNOLOGY FAST 500 COMPANIES IN ASIA PACIFIC (APAC)
    • EIRGENIX RECEIVED "ASIA'S BEST CMO"
    • EIRGENIX RECEIVED THE ACCREDITATION CERTIFICATE OF FOREIGN DRUG MANUFACTURER FROM JAPAN
    • EIRGENIX HELD THE WHOLE NEW "PROTEIN DRUG COMMERCIAL PRODUCTION PLANT" BEAM-RAISING CEREMONY
    • CANCER THERAPEUTIC DRUG EG12014 PASSED THE DOUBLE-BLINDED PHASE I CLINICAL TRIAL
    • EIRGENIX RECEIVED "GRAND WINNER OF BEST BIOPROCESS EXCELLENCE IN TAIWAN"
    • EIRGENIX HELD THE WHOLE NEW "PROTEIN DRUG COMMERCIAL PRODUCTION PLANT" GROUNDBREAKING CEREMONY
    • 2015 TAIWAN BIO-MEDICAL AND NEW AGRICULTURAL INDUSTRY DRAFT COMPETITION AWARDS CEREMONY
    • EIRGENIX AND FORMOSA LABORATORIES COLLABORATE TO ESTABLISH A PLATFORM FOR ADC CMC INTEGRATION SERVIC
    • EIRGENIX DEVELOPS AND MANUFACTURES BIOLOGICS
  • Events
    • Antibody Therapeutic Conference -November-15,2022
    • EIRGENIX AT CPHI WORLDWIDE 2021 IN Frankfurt, Germany
    • EIRGENIX AT BIO-EUROPE® - October 24–26, 2022
    • EIRGENIX AT BIO ASIA-TAIWAN EXHIBITION - JULY 28-31, 2022
    • EirGenix, Inc. joins the 2022 BIO International Convention in San Diego, CA from June 13 to June 16.
    • EIRGENIX AT THE HEALTHCARE + EXPO TAIWAN - DECEMBER 2-5, 2021
    • EIRGENIX AT BIO ASIA-TAIWAN EXHIBITION - NOVEMBER 4-7, 2021
    • EIRGENIX AT CPHI WORLDWIDE 2021 IN MILAN, ITALY
    • EIRGENIX AT 2020 HEALTHCARE+ EXPO TAIWAN - DECEMBER 3-6-2020
    • 【2020 HEALTHCARE+ EXPO TAIWAN】EIRGENIX INC. - YOUR RELIABLE BIOLOGICS PARTNER!
    • EIRGENIX AT BIO ASIA-TAIWAN CONFERENCE AND EXHIBITION - JULY 22-26, 2020
    • EIRGENIX AT HEALTHCARE + EXPO TAIWAN – DECEMBER 5-8, 2019
    • EIRGENIX AT BIO ASIA-TAIWAN CONFERENCE AND EXHIBITION - JULY 25-28, 2019
    • 2018 BIOLOGICS MANUFACTURING KOREA
    • OUTSTANDING RESULTS FROM 2016 BIO INTERNATIONAL CONVENTION
    • 2015 6TH WORLD ADC SUMMIT SAN DIEGO
    • BIO TAIWAN 2015
    • CPHI JAPAN 2015
    • ANTIBODY DRUGS NOVEL BIOLOGICAL SUMMIT 2015
    • BIOTAIWAN CONVENTION 2014
    • COGRATULATE EIRGENIX' SUCCESSFUL EXHIBITION IN BIOTECH JAPAN 2014!

Events

2015 6TH WORLD ADC SUMMIT SAN DIEGO

2015 6TH WORLD ADC SUMMIT SAN DIEGO

 2015/10/19
BIO TAIWAN 2015

BIO TAIWAN 2015

 2015/07/23
CPHI JAPAN 2015

CPHI JAPAN 2015

 2015/04/22
ANTIBODY DRUGS NOVEL BIOLOGICAL SUMMIT 2015

ANTIBODY DRUGS NOVEL BIOLOGICAL SUMMIT 2015

 2015/03/15
BIOTAIWAN CONVENTION 2014

BIOTAIWAN CONVENTION 2014

 2014/07/27
COGRATULATE EIRGENIX' SUCCESSFUL EXHIBITION IN BIOTECH JAPAN 2014!

COGRATULATE EIRGENIX' SUCCESSFUL EXHIBITION IN BIOTECH JAPAN 2014!

 2014/05/19
  • ‹
  • 1
  • 2
  • Sitemap
  • Privacy Policy
  • EIP
copyright © 2023 EirGenix, Inc. all rights reserved.
EirGenix, Inc.
  • Address No. 101, Lane 169, Kangning St., Xizhi Dist, New Taipei City 22180, Taiwan, R.O.C
  • TEL +886-2-7708-0123
  • FAX +886-2-7708-1666
  • E-mail service@eirgenix.com
  • LINKEDIN
  • YOUTUBE